



Functional Characterization of the m⁶A-Dependent Translational Modulator PfYTH.2 in the Human Malaria Parasite

 Ameya Sinha,^{a,b}
 Sebastian Baumgarten,^{c,d,e}
 Amy Distiller,^f
 Emma McHugh,^f
 Patty Chen,^{c,d,e}
 Meetali Singh,^{g,h}
 Jessica M. Bryant,^{c,d,e}
 Jiaqi Liang,^{a,b}
 Germano Cecere,^{g,h}
 Peter C. Dedon,^{b,i}
 Peter R. Preiser,^{a,b}
 Stuart A. Ralph,^f
 Artur Scherf^{c,d,e}

^aSchool of Biological Sciences, Nanyang Technological University, Singapore, Republic of Singapore

^bAntimicrobial Resistance Interdisciplinary Research Group, Singapore-MIT Alliance for Research and Technology, Singapore, Republic of Singapore

^cBiology of Host-Parasite Interactions Unit, Department of Parasites and Insect Vectors, Institut Pasteur, Paris, France

^dCNRS, ERL 9195, Paris, France

^eINSERM, Unit U1201, Paris, France

^fDepartment of Biochemistry and Molecular Biology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Australia

^gMechanisms of Epigenetic Inheritance, Department of Developmental and Stem Cell Biology, Institut Pasteur, Paris, France

^hCNRS, UMR 3738, Paris, France

ⁱDepartment of Biological Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA

Ameya Sinha and Sebastian Baumgarten contributed equally to conducting experiments, analyzing the data, and preparing the manuscript. The order was determined by mutual agreement.

ABSTRACT Posttranscriptional regulation of gene expression is central to the development and replication of the malaria parasite, *Plasmodium falciparum*, within its human host. The timely coordination of RNA maturation, homeostasis, and protein synthesis relies on the recruitment of specific RNA-binding proteins to their cognate target mRNAs. One possible mediator of such mRNA-protein interactions is the N⁶-methylation of adenosines (m⁶A), a prevalent mRNA modification of parasite mRNA transcripts. Here, we used RNA protein pulldowns, RNA modification mass spectrometry, and quantitative proteomics to identify two *P. falciparum* YTH domain proteins (PfYTH.1 and PfYTH.2) as m⁶A-binding proteins during parasite blood-stage development. Interaction proteomics revealed that PfYTH.2 associates with the translation machinery, including multiple subunits of the eukaryotic initiation factor 3 (eIF3) and poly(A)-binding proteins. Furthermore, knock sideways of PfYTH.2 coupled with ribosome profiling showed that this m⁶A reader is essential for parasite survival and is a repressor of mRNA translation. Together, these data reveal an important missing link in the m⁶A-mediated mechanism controlling mRNA translation in a unicellular eukaryotic pathogen.

IMPORTANCE Infection with the unicellular eukaryotic pathogen *Plasmodium falciparum* causes malaria, a mosquito-borne disease affecting more than 200 million and killing 400,000 people each year. Underlying the asexual replication within human red blood cells is a tight regulatory network of gene expression and protein synthesis. A widespread mechanism of posttranscriptional gene regulation is the chemical modification of adenosines (m⁶A), through which the fate of individual mRNA transcripts can be changed. Here, we report on the protein machinery that “reads” this modification and “translates” it into a functional outcome. We provide mechanistic insight into one m⁶A reader protein and show that it interacts with the translational machinery and acts as a repressor of mRNA translation. This m⁶A-mediated phenotype has not been described in other eukaryotes as yet, and the functional characterization of the m⁶A interactome will ultimately open new avenues to combat the disease.

KEYWORDS *Plasmodium falciparum*, m⁶A mRNA methylation, translational repression, PfYTH, malaria parasite

Citation Sinha A, Baumgarten S, Distiller A, McHugh E, Chen P, Singh M, Bryant JM, Liang J, Cecere G, Dedon PC, Preiser PR, Ralph SA, Scherf A. 2021. Functional characterization of the m⁶A-dependent translational modulator PfYTH.2 in the human malaria parasite. *mBio* 12:e00661-21. <https://doi.org/10.1128/mBio.00661-21>.

Editor Stephen L. Hajduk, University of Georgia

Copyright © 2021 Sinha et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Sebastian Baumgarten, sebastian.baumgarten@pasteur.fr.

Received 9 March 2021

Accepted 17 March 2021

Published 27 April 2021

The unicellular apicomplexan parasite *Plasmodium falciparum* is the causative agent of the most virulent form of human malaria, a mosquito-borne infectious disease which remains a global health threat (1). All symptoms of the disease are caused by the asexual replication of the parasite within human red blood cells (RBCs). During the 48-h intraerythrocytic developmental cycle (IDC), each parasite replicates and creates up to 32 daughter cells that reinfect new RBCs. During the IDC, monocistronic gene expression is tightly controlled at least in part by a family of apicomplexan-specific ApiAP2 transcription factors and epigenetic coactivators (2–4). The mRNAs of a gene reach peak abundance only once per cycle (5), which corresponds to a time preceding the period when the encoded protein is most required. Selective silencing of subtelomeric and central chromosomal regions by heterochromatin further orchestrates the timely expression of variant surface antigens (6) and sexual commitment (7, 8). In addition to epigenetic and transcriptional control of mRNA abundances, extensive modulation of mRNA stability and translational efficiency occurs throughout the IDC (9–11). However, a mechanism mediating such posttranscriptional control on a transcriptome-wide level remained unknown.

Recently, N⁶-methylation of adenosines (m⁶A) at internal positions of mRNA transcripts has been identified as the most abundant mRNA modification in *P. falciparum* (12). Due to the exceptionally high adenosine content of the parasite's mRNA transcriptome (~45%), global m⁶A levels exceed those measured among other eukaryotes. In addition, m⁶A levels are highly dynamic and double over the course of the IDC, suggesting m⁶A is the basis of a key posttranscriptional control mechanism in the parasite. Similar to what has been observed in model eukaryotes (13), m⁶A methylation in *P. falciparum* inversely correlates with mRNA stability. However, m⁶A-modified mRNAs tend to also show lower translational efficiencies (12), suggesting a new m⁶A-mediated phenotype that has so far not been described in eukaryotes.

To achieve a functional outcome, m⁶A recruits specific “reader” proteins (14). Such proteins, especially those containing a YT521-B homology (YTH) domain, have been identified as evolutionarily conserved in many eukaryotes (Fig. 1A) and can affect a multitude of cellular processes via modulation of mRNA degradation and alternative splicing as well as the function of noncoding RNAs (15). In addition to an evolutionarily conserved m⁶A core “writer” complex, *P. falciparum* harbors two proteins that contain a YTH domain: PfYTH.1 (PF3D7_1419900) and PfYTH.2 (PF3D7_0309800) (12). During the IDC, these two genes reach peak transcription in the late ring and early trophozoite stages (i.e., 16 to 20 h postinfection [hpi]). However, while PfYTH.1 is exclusively expressed during the IDC, PfYTH.2 is transcribed at even higher levels in transmission stages (i.e., gametocytes and sporozoites) (Fig. S1A). Outside their conserved YTH domain, PfYTH.1 and PfYTH.2 are highly divergent (12), suggesting that the two proteins have distinct functions. However, the m⁶A-binding ability of these PfYTH proteins or their specific roles in dictating the functional outcome of m⁶A in *P. falciparum* remain unknown.

Here, using RNA modification mass spectrometry and RNA-mediated protein immunoprecipitation combined with quantitative proteomics, we demonstrate that PfYTH.1 and PfYTH.2 are m⁶A-binding proteins. We show that PfYTH.2 is essential for normal parasite growth and associates with the translational machinery during the IDC. Inducible knock sideways followed by ribosome profiling showed that PfYTH.2 is likely a repressor of mRNA translation, revealing a role for m⁶A mRNA methylation in the fine-tuning of gene expression in *P. falciparum*.

RESULTS

Identification of PfYTH proteins as m⁶A “readers”. To identify putative m⁶A-binding proteins in the *P. falciparum* proteome, we first performed an unbiased protein pulldown using a synthetic RNA oligonucleotide containing five repetitions of the consensus m⁶A motif (GGm⁶ACA) and a nonmethylated control RNA oligonucleotide of identical sequence and length but without m⁶A methylation (i.e., 5 repetitions of




FIG 1 PfYTH.1 and PfYTH.2 are m⁶A-binding proteins in *P. falciparum*. (A) Model for the mode of action of the PfMT-A70 m⁶A methylation complex and putative m⁶A-binding “reader” proteins mediating mRNA degradation and translational repression in *P. falciparum*. (B) TMT-based quantification of proteins that were preferentially pulled down *in vitro* either with an m⁶A-methylated (right half) or unmethylated (left half) RNA (see also Fig. S1B in the supplemental material). The x axis represents the average intensity of the TMT reporter ion in the m⁶A-methylated oligonucleotide pull-down over those in the unmethylated oligonucleotide pull-down. (C) Stain-free gel of recombinant PfYTH.2 with an N-terminal glutathione S-transferase (GST) tag. The lower band corresponds to free GST. Numbers on the left show size in kilodaltons. The GST-PfYTH.2 fusion protein is detectable at ~50 kDa (calculated weight, 60.1 kDa). (D) Dot blot assay showing binding of recombinant PfYTH.2 to m⁶A-methylated RNA oligonucleotides (Fig. S1B) in a concentration-dependent manner (top, m⁶A) but no binding to the identical RNA oligonucleotide without m⁶A (bottom, A). Concentrations of spotted RNA oligonucleotide are indicated above the plot. Signal was obtained using an anti-GST antibody (GE Healthcare 27457701). (E) LC-MS/MS measurements of m⁶A/A ratios in native *P. falciparum* mRNA before (input) and after (supernatant [SN]) incubation with recombinant PfYTH.2 protein (IP). m⁶A is depleted in the non-PfYTH.2-bound fraction collected after incubation and enriched in the PfYTH.2-bound fraction. *P* values were calculated with a two-sided independent-samples *t* test. Average and median values are shown for four individual experiments, represented as dots.

GGACA) (see Fig. S1B in the supplemental material). Quantitative tandem mass tag (TMT) proteomics identified PfYTH.1 (PF3D7_1419900) as the most significantly enriched protein in the pull-down with the methylated RNA oligonucleotide compared to that with the nonmethylated RNA oligonucleotide. Other proteins that were significantly enriched in the methylated oligonucleotide pull-down included three of the four ALBA DNA/RNA-binding proteins (ALBA2 to -4) (Fig. 1B; see also Table S1). In addition, we found another putative RNA-binding protein (PF3D7_0605100) to be significantly more abundant in the methylated oligonucleotide pull-down. This protein encodes four K homology (KH) domains and was named PfKH.1. In contrast, the poly(A)-binding protein 2 (PABP2; PF3D7_0923900) and serine/arginine splicing factor 1 (SR1; PF3D7_0517300) were significantly enriched in the nonmethylated RNA oligonucleotide pull-down (Fig. 1B; Table S1).

Besides PfYTH.1, *P. falciparum* harbors a second YTH domain protein, called PfYTH.2 (PF3D7_0309800). Evolutionarily, both PfYTH.1 and PfYTH.2 are similar to YTH domain family (YTHDF) proteins found in humans and ECT2 in *Arabidopsis* (Fig. S1C). PfYTH.1 has a length similar to that of human YTHDF and includes a C-terminal YTH domain and an N-terminal zinc finger domain with an intermediate intrinsically disordered region (Fig. S1D). In contrast, PfYTH.2 has an N-terminal YTH domain, is half the length of PfYTH.1, and, in general, shows little homology to other eukaryotic YTH proteins. Yet, key residues of the YTH domain involved in m⁶A binding in other eukaryotes are conserved in both PfYTH.1 and PfYTH.2 (Fig. S1E). Given the higher potential of selective drug development with more divergent reader proteins, we next aimed to also identify PfYTH.2 as an m⁶A-binding protein in *P. falciparum*. First, an N-terminally

glutathione *S*-transferase (GST)-tagged recombinant full-length PfYTH.2 protein was produced in *Escherichia coli* (Fig. 1C; Fig. S1F). In a dot blot assay using the same synthetic RNA oligonucleotides as for the *de novo* identification of m⁶A readers (Fig. S1B), recombinant PfYTH.2 bound to the methylated oligonucleotide in an RNA concentration-dependent manner. In contrast, recombinant PfYTH.2 did not bind to a nonmethylated control RNA oligonucleotide (Fig. S1B) of identical sequence and length (Fig. 1D). In contrast, two individual mutations (W46L and D143E) of conserved residues in PfYTH.2 known to facilitate m⁶A binding (16, 17) (Fig. S1E) led to decreased binding of the mutated PfYTH.2 to m⁶A (Fig. S1G), also indicating that the binding signal is dependent on the PfYTH.2 protein and not possible impurities or the GST tag of the recombinant protein.

To assess whether PfYTH.2 binds m⁶A in native *P. falciparum* mRNA, we next performed an *in vitro* protein-mRNA pulldown (Fig. S1H). Recombinant PfYTH.2 was immobilized on anti-GST magnetic beads and incubated with poly(A)-RNA purified from parasites at 36 hpi. Levels of m⁶A and N⁷-methylguanosine (m⁷G) in the input, supernatant, and immunoprecipitate were measured by liquid chromatography coupled to triple quadrupole mass spectrometry (LC-MS/MS). We observed a significant enrichment of m⁶A in the PfYTH.2-bound fraction after normalization with the corresponding unmodified nucleoside (rA) (Fig. 1E). Conversely, m⁶A/rA levels were substantially depleted in the supernatant compared to levels in the input (Fig. 1E). This trend was not observed for m⁷G in these same samples, suggesting that PfYTH.2 preferentially binds to m⁶A (Fig. S1I).

PfYTH.2 associates with proteins involved in mRNA translation. To investigate the function of PfYTH.2 *in vivo*, we added a green fluorescent protein (GFP) tag flanked on either side by two FK506 binding protein (FKBP) domains to the C terminus of the endogenous copy of PfYTH.2 (PfYTH.2-sandwich) (see Fig. S2A) using the selection-linked integration approach as in reference 18. Integration of the construct was confirmed by PCR (Fig. S2B) and sequencing, and a Western blot analysis showed the PfYTH.2 fusion protein at the expected size predominantly in the cytoplasm of trophozoites (Fig. 2A). An immunofluorescence assay (IFA) confirmed this localization of the PfYTH.2 fusion protein primarily to the cytoplasm as well (Fig. 2B).

To identify proteins that interact with PfYTH.2, we performed protein co-immunoprecipitation with an anti-GFP antibody for trophozoite parasites followed by LC-MS. We identified 12 specific proteins (present with ≥ 2 unique peptides in at least 2 of 3 PfYTH.2-sandwich replicates and not present in the control) (Fig. S2D), including multiple proteins putatively associated with the translation machinery: three subunits of the eukaryotic initiation factor 3 (eIF3a, -c, and -h), two polyadenylate binding-like proteins (PABPs), and three proteasomal proteins linked to protein degradation. A third PABP (PABP1; PF3D7_1224300) was also found to be substantially more enriched but not uniquely present in the PfYTH.2 co-immunoprecipitation compared to that in the control GFP immunoprecipitation in wild-type (WT) parasites. In addition, we found gamete antigen 27 (PF3D7_1302100) and a CELF3-like protein (PF3D7_0823200) to specifically associate with PfYTH.2, among others (see Table S2). A gene ontology (GO) enrichment analysis of the putative PfYTH.2 interacting proteins showed a significant enrichment of molecular functions “RNA binding”, “translation initiation factor activity”, and “threonine-type endopeptidase activity” (Fig. 2C). In contrast, PfYTH.2 was not found to interact with PfYTH.1, further suggesting that the two proteins have independent mode of actions.

To further reveal a possible association of PfYTH.2 with either mRNA ribonucleoprotein complexes (mRNP) or the translation machinery, we fractionated non-cross-linked, early trophozoite PfYTH.2-sandwich cell extracts on a sucrose gradient. Western Blot analysis of the different fractions showed PfYTH.2 to be present in the mRNP, monosome, and polysome fractions (Fig. 2D). Together with the interaction of PfYTH.2 with other RNA-binding proteins and translational regulators, these data suggest that




FIG 2 PfyTH.2 associates with the translational machinery. (A) Western blot analysis using anti-GFP antibodies to visualize PfyTH.2-sandwich (expected size, ~116 kDa) shows the expression of the fusion protein and its localization to the cytoplasm. Histone H3 (PfH3) and aldolase (PfAldolase) serve as markers for the cytoplasmic (C) and nuclear (N) fractions. Numbers on the left indicate protein size in kilodaltons. (B) Immunofluorescence assay using anti-GFP antibodies shows the main localization of PfyTH.2 (green) to the parasite cytoplasm. Nucleus stained with Hoechst (blue). Bar, 2 μ m. (C) Gene ontology (GO) enrichment analysis of proteins that were co-immunoprecipitated specifically with PfyTH.2 and identified by mass spectrometry (see Table S2). (D) Absorbance (260 nm) of a sucrose gradient of PfyTH.2-sandwich cell lysates (top) showing different cell fractions containing free mRNA ribonucleoprotein complexes (mRNP), small and large ribosome subunits (40S and 60S), monosomes (80S), and mRNAs associated with multiple ribosomes (polysomes). (Bottom) Western Blot using anti-GFP antibodies identifies PfyTH.2 to be present in the mRNP, monosome, and polysome fractions corresponding to the profile above.

PfyTH.2 can associate with free and ribosome-associated mRNAs to possibly modulate mRNA homeostasis and/or translation.

PfyTH.2 is essential for blood-stage development. Since PfyTH.2 was not mutable in a genome-wide mutagenesis screen (19), we generated a strain in which we could perform ligand-inducible relocalization (18) (i.e., knock sideways) of PfyTH.2 to determine the role of this protein in the IDC. For this, a plasmid expressing an FKBP-rapamycin-binding (FRB) domain fused to a plasma membrane-anchored peptide (Lyn) and mCherry (i.e., the “mislocalizer”) was transfected into the PfyTH.2-sandwich strain described above (Fig. S2C). Live-cell microscopy of the resulting strain (PfyTH.2-sandwich^{ML}) showed localization of the Lyn-FRB-mCherry mislocalizer to the plasma membrane (Fig. 3A, top). Addition of the small-molecule ligand rapamycin to the cell culture, which induces dimerization of FKBP and FRB, resulted in the rapid relocalization of PfyTH.2-sandwich to the plasma membrane within 3 h (Fig. 3A, bottom).

To determine if PfyTH.2 knock-sideways leads to a functional knockdown, we compared growth rates with or without rapamycin between the PfyTH.2-sandwich and PfyTH.2-sandwich^{ML} strains. The PfyTH.2-sandwich and PfyTH.2-sandwich^{ML} strains grew at similar rates in the absence of rapamycin, and addition of rapamycin did not affect growth rates of PfyTH.2-sandwich parasites, indicating that these concentrations of rapamycin do not restrict parasite growth (Fig. 3B). However, PfyTH.2-sandwich^{ML} parasites grown in the presence of rapamycin showed a significantly decreased growth rate (Fig. 3B). This indicates that neither modification of the PfyTH.2 with the sandwich fusion nor presence of the mislocalizer affects cell growth, but that the inducible mislocalization of PfyTH.2 affects parasite replication and/or survival, presumably due to a knockdown of PfyTH.2 function.

To assess whether this mislocalization leads to a dissociation of PfyTH.2 and its putative target transcripts, we performed an *in vivo* PfyTH.2 RNA co-immunoprecipitation




FIG 3 PfyTH.2 is essential for blood-stage asexual/replicative cycle. (A) Live-cell imaging of PfyTH.2-sandwich mislocalization following rapamycin addition in PfyTH.2-sandwich^{ML} parasites. Bar, 2 μ m. (B) Growth curve over 4 days of PfyTH.2-sandwich and PfyTH.2-sandwich^{ML} parasites in the presence (250 nM final concentration, +RAP) or absence (–RAP) of rapamycin. Error bars represent standard deviations from six independent experiments. (C) Enrichment (\log_2) of PfyTH.2-bound transcripts in nontreated (–RAP) compared to that in knock-sideways (+RAP) PfyTH.2-sandwich^{ML} cells following PfyTH.2-RNA co-immunoprecipitation. Transcript levels were quantified by RT-qPCR. Blue circles represent \log_2 enrichment values from two independent biological replicates. Black lines represent the means. 0403200, putative pre-mRNA splicing factor; 0934700, putative UBX domain-containing protein; 1027300, peroxiredoxin; 1140200, conserved *Plasmodium* protein, unknown function; 1309300, putative U4/U6 small nuclear ribonucleoprotein PRP3; 1358100, putative Sas10 domain-containing protein.

followed by reverse transcription-quantitative PCR (RIP-qPCR) on formaldehyde cross-linked PfyTH.2-sandwich^{ML} cells that were either treated with rapamycin for 3 h (+RAP) or nontreated (–RAP). All putative target transcripts investigated (i.e., previously identified to have an m⁶A peak [12]) were found to be more abundant under the nontreated condition than under the rapamycin-treated condition (Fig. 3C). This suggests that correct localization of PfyTH.2 within the cell is critical for its function and that its mislocalization does not lead to the relocation of the protein together with its bound transcript but induces the dissociation of the m⁶A reader from its target mRNA and mRNP complex.

PfyTH.2 knockdown leads to an increase in translational efficiency. Given the association of PfyTH.2 with multiple components of the translational machinery, we next assessed the effect of PfyTH.2 knock-sideways on translational efficiencies. Synchronized PfyTH.2-sandwich^{ML} parasites were incubated for 3 h with (+RAP) or without (–RAP) rapamycin, and RNA was harvested at 24 hpi. We performed ribosome profiling by RNase treatment of the protein lysates to digest actively translating polyosomes into individual monosomes that remain associated with the mRNA fragment they were bound to at the time point of sampling (i.e., the ribosome-protected fragments [RPF] shielded from the nuclease). The 80S monosome fraction of the digested lysate was purified from a 10% to 50% sucrose gradient (Fig. 4A, left) followed by gel size selection of the 25- to 32-nucleotide (nt) RPF fraction (Fig. 4A, right). These RPFs were sequenced in parallel with mRNA from the same samples, allowing us to calculate the density (i.e., coverage) of RPFs that correspond to the number of actively




FIG 4 Ribo-seq identifies PfYTH.2 as a modulator of translational efficiency in *P. falciparum*. (A) Absorbance profile of the sucrose gradient (measured at 260 nm) of the RNA harvested from parasites in the absence of rapamycin after RNase I treatment. The 80S monosome fraction (blue) was collected, and the small RNA-containing fraction ranging from 26 to 32 nt was size selected on a 15% TBE-urea gel to enrich for ribosome-protected fragments (right). (B) Box plot showing translational efficiencies (calculated as fragments per kilobase of exon per one million mapped reads [FPKM] RPF/FPKM mRNA) in PfYTH.2-sandwich^{ML} parasites after 3 h incubation without (–RAP, gray) or with 250 nM rapamycin (+RAP, yellow). Center line, median; box limits, first and third quartiles; whiskers, 1.5× interquartile range. *P* values were calculated using a two-sided Mann-Whitney *U* test. *n* = 3,745. (C) Scatterplot showing the log₂ fold change in translational efficiency (ordinate, ΔTE) and total mRNA abundance (abscissa, ΔRNA) between PfYTH.2-sandwich^{ML} parasites after 3 h incubation with (+RAP) or without (–RAP) rapamycin. Blue, transcripts with a log₂FC TE of ≥1 or ≤–1. (D) Histogram showing the hours postinvasion of the RBCs at which genes with a log₂FC in TE of ≥1 (blue) or ≤–1 (gray) are maximally transcribed. Transcription data set derived from reference 9. (E) Box plot of translational efficiencies for transcripts without (no m⁶A) or with an m⁶A peak (m⁶A) measured in PfYTH.2-sandwich^{ML} parasites after 3 h incubation without (–RAP, gray) or with (+RAP, yellow) rapamycin. Center line, median; box limits, first and third quartiles; whiskers, 1.5× interquartile range. *P* values were calculated using a two-sided Mann-Whitney *U* test. No m⁶A, *n* = 3,266; m⁶A, *n* = 481 (data set derived from reference 12). (F) Box plot of translational efficiencies measured in PfYTH.2-sandwich^{ML} parasites after 3 h incubation without –RAP, gray) or with (+RAP, yellow) rapamycin for m⁶A-methylated transcripts as a function of m⁶A peak density (m⁶A peaks per kilobase of exon [ppkb]). Center line, median; box limits, first and third quartiles; whiskers, 1.5× interquartile range. m⁶A ppkb of ≤0.5, *n* = 388; m⁶A ppkb of 0.5 to <1, *n* = 144; m⁶A ppkb of ≥1, *n* = 72 (data set derived from reference 12).

translating ribosomes. Normalized to the relative abundance of the mRNA transcript obtained from the mRNA sequencing (mRNA-seq) performed in parallel, this provides a relative measure of translational efficiencies for each transcript (TE) (see Table S3) (20). We observed an overall positive correlation with two previously published *P. falciparum* TE data sets (10, 21), despite differing sampling time points, RPF preparation protocols, and TE calculation formulas (21), suggesting that our method was robust (see Fig. S3A).

A comparison of translational efficiencies for all genes showed a significant overall increase in TE following knock-sideways of PfYTH.2 (Fig. 4B; Fig. S3B). A gene-specific calculation of TE revealed a similar pattern, with significantly more transcripts showing an increase (log₂ fold change [FC] [ΔTE] ≥ 1, *n* = 128) compared to a decrease (log₂FC [ΔTE] ≤ –1, *n* = 45) in TE (two-tailed χ^2 , *P* < 0.0001) (Fig. 4C; Table S3). In contrast to

the changes in TE (Δ TE), changes in mRNA abundance (Δ RNA) are less pronounced, suggesting that PfYTH.2 knock-sideways primarily affects ribosome occupancy rather than underlying mRNA abundance (Fig. 4C). Most transcripts with increased TE (\log_2 FC ≥ 1) reach peak transcription at 24 to 26 hpi (i.e., the time point of sample collection) (9), whereas a similar pattern is not observed for transcripts with decreased TE (\log_2 FC ≤ -1) (Fig. 4D). Surprisingly, following knock sideways of PfYTH.2, TE significantly increases for transcripts with and without identified m⁶A peaks (12), which might be due to an incomplete annotation of m⁶A sites which was performed using an anti-m⁶A antibody-based approach (12) (Fig. 4E). A further classification of m⁶A-methylated transcripts based on m⁶A peak density revealed an inverse correlation between TE and m⁶A density (Fig. 4F) in the untreated parasites. Following PfYTH.2 knock-sideways, TE increases independently of m⁶A density (Fig. 4F); however, transcripts with higher m⁶A density show slightly higher average changes in TE (Fig. S3C). Altogether, the increase in translational efficiencies following inducible PfYTH.2 knock-sideways suggests that this protein is an m⁶A-sensitive modulator of translation with a putatively repressive function.

DISCUSSION

In this study, we identify two YTH proteins as bona fide m⁶A-binding factors in the human malaria parasite *P. falciparum*. Characterization of the divergent PfYTH.2 showed that it interacts with components of the translational machinery and serves a repressive function with regard to translation. The YTH domain has been identified as an evolutionarily conserved m⁶A-binding moiety found in a range of m⁶A reader proteins in model eukaryotes, including yeast, fly, *Arabidopsis*, and mammal. Importantly, while certain YTH domain proteins in mammalian cells are functionally redundant (13), the overall sequence divergence and the distinct expression profiles of the two *P. falciparum* YTH proteins suggest that they have nonredundant functions. In line with the conservation of key residues within the YTH domain, which are involved in RNA and m⁶A binding in other eukaryotes, we demonstrated that PfYTH.2 is an m⁶A-binding protein with dot blot assay and RNA pulldown followed by LC-MS/MS. While our attempt to identify other m⁶A readers showed binding for PfYTH.1, the lack of PfYTH.2 in the oligonucleotide pulldown experiment might be either due to suboptimal ionization during mass spectrometry or due to its short length, which could require a more sensitive mass spectrometry analysis to identify the fewer corresponding peptides coming from this protein. Indeed, we note that PfYTH.2 is sparsely detected in other *P. falciparum* proteomics experiments and does not feature high peptide counts even in the targeted PfYTH.2 protein co-immunoprecipitation (see Table S2 in the supplemental material). In addition, it is also possible that despite similar mRNA expression levels, PfYTH.1 is the predominant m⁶A-binding protein at this stage of parasite development. Nevertheless, the m⁶A oligonucleotide pulldown approach also identified other putative m⁶A reader proteins, among which is the K homology domain-containing protein PfkH.1. Indeed, the KH domain-containing protein IGF2BP1 was recently characterized as a putative m⁶A reader in mammalian cells (22, 23). Both IGF2BP1 and PfkH.1 share a similar domain architecture that includes two highly conserved tandem KH domain repeats (Fig. S3D and E). In addition, several other KH domain-containing proteins, including the fragile X mental retardation protein (FMRP), have been identified in mammalian m⁶A interactome screens as putative m⁶A readers (24, 25). However, while it is possible that the KH domain is an evolutionarily conserved m⁶A-binding moiety, it is similarly possible that PfkH.1 is a PfYTH.1-interacting protein, as recently reported in *Drosophila melanogaster* (26), and thus appears as enriched in the oligonucleotide pulldown experiment.

PfYTH.2 was not mutable in a PiggyPac mutagenesis screen (19), suggesting that this gene is essential for parasite survival, similar to other components of the m⁶A pathway (12). Thus, we used an inducible knock-sideways approach to functionally knock down PfYTH.2, leading to the inhibition of parasite growth likely due to the

dissociation of PfYTH.2 from its target transcripts, as evidenced by our RIP-qPCR data. The growth deficiency following PfYTH.2 further suggest that its function cannot be complemented by PfYTH.1, which is also highlighted by the negligible changes in gene expression of PfYTH.1 (\log_2 fold change, -0.06) or PfYTH.2 (\log_2 fold change, 0.04) on the PfYTH.2 knock-sideways condition (Table S3). Overall, this provides further evidence for the divergent functions of these two proteins.

A knockdown with a duration of only 3 h and subsequent comparative ribosome profiling revealed that PfYTH.2 likely acts as a repressor of mRNA translation, especially for high-abundance transcripts. These data suggest that PfYTH.2-mediated modulation of translation could act as a counterbalance to fine-tune translation of an otherwise more rigid transcriptional program. Importantly, an increase in translational efficiency was seen for mRNA transcripts with or without an m⁶A peak (as identified by m⁶A-seq [12]) following PfYTH.2 knock-sideways. Although our dot blot and LC-MS/MS analyses showed a clear preference of PfYTH.2 for m⁶A-modified transcripts, it is possible that PfYTH.2 might also act on nonmethylated mRNA transcripts. On the other hand, it is more likely that a substantial fraction of the transcripts categorized here as “nonmethylated” do actually contain m⁶A, as the number of identified m⁶A peaks is an underestimate of the true extent of m⁶A transcript modification in *P. falciparum*. Indeed, our previous quantitative LC-MS/MS measurements of global m⁶A levels suggested that there are up to 10 times more m⁶A residues than m⁶A peaks that were annotated using an antibody-based approach (12). Thus, many of the transcripts categorized as nonmethylated could in fact also contain m⁶A methylation sites.

The protein co-immunoprecipitation of PfYTH.2 identified multiple proteins that provide possible insight into the putative function of PfYTH.2 but for which functional studies are largely missing. Among those are several polyadenylate binding proteins (PABPs), which are well annotated and conserved in *Plasmodium* (27) and which are known regulators of mRNA translation in other eukaryotes (28). While the exact molecular function of other interacting proteins such as the CELF3-like protein or gamete antigen 27 in *P. falciparum* remains unknown, we also identified several components of the proteasome, which in a recent protein interaction screen were found to closely associate with the eIF3 complex in *P. falciparum* (29). The interaction of PfYTH.2 with multiple components of the eIF3 complex, in combination with our ribosome profiling (Ribo-seq) data and the presence of PfYTH.2 in in the mRNP but also the monosome and polysome fractions, strongly suggests that this m⁶A reader can act as a modulator of mRNA translation.

The question remains as to how PfYTH.2 might repress translation. The direct interaction of PfYTH.2 with PABPs and multiple eIF3 subunits but not with other proteins of the translation initiation complex (e.g., eIF4) or ribosomal proteins could suggest that PfYTH.2 impairs assembly of the intact translational machinery. Translational repression via interference with the translation initiation machinery has been observed in multiple model systems and can be mediated by microRNAs (miRNAs) (30), the UNR/Sxl complex in *D. melanogaster* (31), or the eIF4 binding protein 1 (32). On the other hand, the presence of PfYTH.2 in polysome fractions could also point toward a steric inhibition of ribosomes during translation elongation. Finally, cytoplasmic PfYTH.2 could also sequester m⁶A-methylated transcripts away from the translational machinery, leading to translational repression. Indeed, m⁶A-mediated mRNA sequestration by RNA-binding proteins and formation of biomolecular condensates was recently shown to coincide with translational repression (33). In addition, eIF3, PABP1, and the YTH-domain family protein 2 are known components of biomolecular condensates such as stress granules in mammalian cells (33). Importantly, PABP1 also colocalizes with translationally repressed biomolecular condensates in the host-to-vector transmission stage (i.e., gametocytes) and interacts with other translational repressors in *Plasmodium* (34, 35).

Widespread translational repression has been observed to the highest extent in gametocytes and sporozoites (i.e., the vector-to-host transmission stage) (36, 37). As PfYTH.2 is most highly expressed in these stages (Fig. S1A), it is possible that this protein is also involved in the regulation of translation in these transmission stages. What

remains unclear, however, is whether PfYTH.1 and PfYTH.2 specifically target different cohorts of mRNA transcripts or m⁶A methylation sites, especially at life cycle stages such as the IDC, when these proteins show similar expression patterns.

In conclusion, here we identify two YTH domain proteins as m⁶A-binding factors in *P. falciparum*. The identification of these proteins will be instrumental in further understanding how the prevalent m⁶A modification of the transcriptome in this unicellular pathogen is translated into distinct biological outcomes across the parasite life cycle.

MATERIALS AND METHODS

Parasite culture. Asexual blood-stage *P. falciparum* parasites (strain 3D7) were cultured as described previously (15). Briefly, parasites were cultured in human red blood cells (RBCs) in RPMI 1640 culture medium (Thermo Fisher 22400097) supplemented with 10% (vol/vol) AlbuMAX I (Thermo Fisher 11020039), hypoxanthine (0.1 mM final concentration; CC-Pro Z-41-M), and 10 mg gentamicin (Sigma G1397-10ML) at 4% hematocrit and under 5% O₂, 3% CO₂, at 37°C. Red blood cells were obtained from the Etablissement Français du Sang with approval number HS 2016-24803. Parasite development was monitored by Giemsa staining.

For sampling of highly synchronous parasites during the IDC, the synchronous schizonts were enriched by plasmagel flotation shortly before reinvasion, followed by a sorbitol lysis 6 h later. The 0-h time point was considered to be 3 h after plasmagel flotation. Parasites were collected at 4% hematocrit and ~2% to 3% parasitemia.

Parasite growth assay. To measure parasite growth kinetics, PfYTH.2-sandwich and PfYTH.2-sandwich^{ML} parasites were tightly synchronized and grown either in the presence or absence of 250 nM rapamycin (Sigma R8781). The growth curve was replicated in three distinct batches of RBCs on a 96-well plate in 200 μl complete culture medium per well (and 2 μg/ml blasticidin for the PfYTH.2-sandwich^{ML} replicates). Each day, 5 μl of cell culture was collected and fixed in 45 μl 0.025% glutaraldehyde-phosphate-buffered saline (PBS) for 60 min at 4°C. To quench the reaction, parasites were spun down (5 min, 3,250 × g, 4°C), the supernatant was removed, and cells were suspended in 200 μl 15 mM NH₄Cl-PBS. Parasite nuclei were stained using SYBR green (Sigma S9430) for 30 min and (non)infected RBCs were counted on a CytoFlexS flow cytometer (Beckman Coulter).

Recombinant expression of PfYTH.2. The full-length coding sequence of the PfYTH.2 gene (PF3D7_0309800) was PCR amplified from cDNA to remove introns and cloned into a pGEX expression vector. The recombinant protein carrying an N-terminal GST tag was made in BL21(DE3) bacteria. The bacterial pellet was lysed (50 mM Tris, 50 mM NaCl, 5 mM EDTA with protease inhibitor [Sigma 4693159001]), sonicated, and centrifuged (18,000 × g for 60 min at 4°C) to obtain the soluble fraction, which was allowed to bind with glutathione Sepharose beads (GE Healthcare) at 4°C. The beads were washed with 5 mM EDTA-PBS (pH 7.4) followed by ATP buffer (50 mM Tris, 2 mM ATP, 10 mM MgSO₄, pH 7.4), and the recombinant protein was then eluted with elution buffer (50 mM Tris, 10 mM reduced glutathione, pH 8). Two PfYTH.2 mutants (W46L and D143E) were generated by PCR (PfuUltra; Agilent) using mutagenesis primers (see Table S4 in the supplemental material) and the pGEX-PfYTH.2 plasmid as the template. Recombinant protein expression and purification were performed as described above. Purified recombinant proteins were migrated on gel (Mini-Protean TGX stain-free gel; Bio-Rad) and transferred to membrane (Trans-Blot Turbo; Bio-Rad). Western blotting was performed by overnight incubation with anti-GST antibody (GE Healthcare 27457701) at 4°C with gentle agitation. The membrane was rinsed three times with PBS with Tween 20 (PBST) and then incubated with horseradish peroxidase (HRP)-coupled secondary antibody (donkey anti-goat IgG-HRP; Santa Cruz sc-2020). The membrane was rinsed as described above and revealed by chemiluminescence (Thermo Fisher 34580). Gels and membranes were imaged with a ChemiDoc XRS+ (Bio-Rad).

Dot blot assay. Positively charged nylon membranes (GE Healthcare RPN303B) were rinsed with ultrapure water, allowed to dry, and then spotted with three different concentrations (1 μg, 100 ng, and 10 ng) of m⁶A or A oligonucleotide (synthesized by GE Dharmacon) (Fig. S1B). The spots were allowed to dry before the RNA was UV cross-linked. Membranes were rinsed in PBST and then blocked with 5% low-fat milk in PBST for 1 h. Ten micrograms of purified recombinant protein was added and incubated for 2 h at room temperature with gentle agitation. Membranes were rinsed three times with PBST for 10 min each, followed by overnight incubation with an anti-GST antibody (GE Healthcare 27457701) at 4°C with gentle agitation. The membrane was rinsed three times with PBST and then incubated with HRP-coupled secondary antibody (donkey anti-goat IgG-HRP; Santa Cruz sc-2020). The membrane was rinsed as described above, developed by chemiluminescence (Thermo Fisher 34580), and imaged with a ChemiDoc XRS+ (Bio-Rad).

In vitro RNA pulldown. Total RNA from highly synchronous parasites was extracted from samples collected at 36 hpi. Briefly, red blood cells were lysed with 0.075% saponin, and the parasite cell pellet was washed once with Dulbecco's PBS (DPBS) and then resuspended in 700 μl QIAzol (Qiagen 79306). Total RNA was extracted using the miRNeasy minikit (Qiagen 217004) according to the manufacturer's instructions, followed by poly(A) RNA enrichment using the Dynabeads mRNA purification kit (Thermo Fisher 61006). Five hundred nanograms of mRNA was diluted to 100 μl and mixed with 100 μl of 2× IPP buffer (300 mM NaCl, 0.2% NP-40, 20 mM Tris [pH 7.4], 80 U/ml RNase inhibitor). Twenty microliters of mRNA at this concentration was saved as input sample for m⁶A analysis. For each sample, 50 μl GST-affinity magnetic beads (Thermo Fisher 88821) were washed 2× with 200 μl of IPP buffer.

Recombinant PfYTH.2 was concentrated (Vivaspin; GE Healthcare) and buffer exchanged into IPP

buffer (150 mM NaCl, 0.1% NP-40, 10 mM Tris [pH 7.4], 40 U/ml RNase inhibitor). One hundred microliters of recombinant PfYTH.2 in IPP buffer at a concentration of 4.8 μ M was then incubated with GST-affinity magnetic beads for 2 h at 4°C on a rotator. The PfYTH.2-GST-bound beads were then washed 3 times with 200 μ l IPP buffer and incubated with 180 μ l of mRNA for 4 h on a rotator at 4°C. The first unbound flowthrough was saved for analysis. The beads were then washed 4 times with 200 μ l of IPP buffer, and QIAzol was added to the collected samples (input, flowthrough, and the PfYTH.2-bound mRNAs). The RNA was purified according to the manufacturer's instructions using solid-phase extraction (Thermo Fisher K157001). The purified fraction was dissolved in 50 μ l water.

Protein-RNA pulldown and protein mass spectrometry. Magnetic streptavidin beads (Thermo Fisher 65001) were washed and prepared as per the manufacturer's instructions and resuspended in 2 \times BW buffer (10 mM Tris-HCl [pH 7.5], 1 mM EDTA, 2 M NaCl) at a final concentration of 5 μ g/ μ l. An equal volume of RNA baits either with or without m⁶A were immobilized on the beads via a 5' biotin tag (Fig. S1B). For each reaction mixture, 3.5 μ g (400 pmol) of RNA oligonucleotides was incubated with 50 μ l (125 μ g) of beads for 15 min at room temperature using gentle rotation. The RNA-coated beads were separated with a magnet for 3 min and washed thrice with 1 \times BW buffer and once with lysis buffer (25 mM Tris-HCl [pH 7.5], 10 mM NaCl, 1% IGEPAL, 1.5 mM MgCl₂, protease inhibitor). Trophozoite-stage parasites were separated from the host red blood cells by incubation with 0.075% saponin in PBS followed by centrifugation for 4 min at 2,400 \times g. The pellet was washed twice with ice-cold PBS, resuspended in 10 volumes of lysis buffer, and incubated on ice for 30 min. This suspension was then transferred to a prechilled bouncer homogenizer and lysed with 200 strokes. The suspension was centrifuged at 13,000 \times g at 4°C to pellet the insoluble fraction. One hundred microliters of the parasite lysate was applied to the beads for 4 h on a gentle rotator at 4°C. The beads were subsequently washed thrice with the lysis buffer followed by three washes of 25 mM ammonium bicarbonate. The beads were then reduced, alkylated, digested, and desalted. Protein peptides were subsequently labeled with TMT labels (Thermo Fisher 901110) as per the manufacturer's instructions.

The protein mass spectrometry was performed as described previously (15). Briefly, peptides were separated by reverse-phase high-performance liquid chromatography (HPLC) (Thermo Easy nLC1000) using a commercial analytical column (Thermo Acclaim PepMax100) over a 90-min gradient before nano-electrospray using an Orbitrap Fusion spectrometer (Thermo Scientific). The mass spectrometer was operated in a data-dependent mode. Full-scan MS parameters were as follows: resolution of 70,000 across 350 to 2,000 *m/z*, automatic gain control (AGC) of 3e⁶, and maximum injection time (IT) of 50 ms. The full MS scan was followed by MS/MS for the top 15 precursor ions in each cycle with a normalized collision energy (NCE) of 28 and dynamic exclusion of 30 s. Raw mass spectral data files (.raw) were searched using Proteome Discoverer (Thermo Fisher) and Mascot (version 2.4.1) (38). Mascot search parameters were as follows: 10 ppm mass tolerance for precursor ions, 15 mmu for fragment ion mass tolerance, 2 missed cleavages of trypsin, fixed modification was carbamidomethylation of cysteine, variable modifications were methionine oxidation, serine, threonine, and tyrosine phosphorylation, and camthiopronoyl. Only peptides with a Mascot score of greater than or equal to 25 and an isolation interference of less than or equal to 30 were included in the data analysis.

Analysis of mRNA modifications by LC-MS/MS. The input, flowthrough, and PfYTH.2-bound mRNA was hydrolyzed enzymatically as described previously (15) using the following components in the buffer mix: 10 mM Tris-HCl (pH 7.9), 1 mM MgCl₂, 5 U Benzonase (Merck 71206), 50 μ M desferrioxamine (Sigma D9533), 0.1 μ g/ μ l pentostatin (Sigma SML0508), 100 μ M butylated hydroxytoluene (Sigma W218405), 0.5 μ g/ μ l tetrahydrouridine (Calbiochem 584222), 5 U bacterial alkaline phosphatase (Thermo Fisher 18011015), and 0.05 U phosphodiesterase I (Sigma P3243). Hypersil GOLD aQ column (100 mm by 2.1 mm, 1.9 μ m; Thermo Scientific 25305) was used to resolve the digested ribonucleosides in a two-buffer eluent system (buffer A, 0.1% formic acid in water; buffer B, 0.1% formic acid in acetonitrile). HPLC was performed at a flow rate of 300 μ l/min at 25°C. The gradient of 0.1% formic acid in acetonitrile was as follows: 0 to 12 min, held at 0%; 12 to 15.3 min, 0% to 1%; 15.3 to 18.7 min, 1% to 6%; 18.7 to 20 min, held at 6%; 20 to 24 min, 6% to 100%; 24 to 27.3 min, held at 100%; 27.3 to 28 min, 100% to 0%; 28 to 41 min, 0%. The HPLC column was directly connected to an Agilent 6490 triple quadrupole mass spectrometer with electrospray ionization (ESI) Jetstream ionization operated in positive-ion mode. The voltages and source gas parameters were as follows: gas temperature, 50°C; gas flow, 11 liters/min; nebulizer, 20 lb/in²; sheath gas temperature, 300°C; sheath gas flow, 12 liters/min; capillary voltage, 1,800 V; and nozzle voltage, 2,000 V. The molecular transition ions were quantified in multiple-reaction monitoring (MRM) mode as in reference 21.

Identification and quantification of mRNA modifications by LC-MS/MS. LC/MS data were extracted using the MassHunter qualitative and quantitative analysis software (version B06.00). To account for any background signal possibly contributing from the salts and enzymes in the digestion buffer, the signal intensity (i.e., area under the curve) for each ribonucleoside was first subtracted from a matrix sample (without RNA). To calculate relative levels of each ribonucleoside and to adjust for different injection amounts of RNA in each sample, the matrix-corrected intensity of the m⁶A was then divided by the intensity of the canonical ribonucleoside (i.e., rA).

Generation of tagged PfYTH.2 cell lines and knock-sideways. To generate a mislocalizable GFP-tagged version of PfYTH.2, we integrated two FK506 binding protein (FKBP) domains, followed by GFP, followed by two more FKBP domains to the 3' end of the endogenous copy of the PfYTH.2 gene. This was followed by a 2A skip peptide and the neomycin resistance protein to allow integration of the whole cassette using the selection-linked integration approach described by Birnbaum and colleagues (18) (Fig. S2A). A 528-nt homology region at the 3' end of PF3D7_0309800 was amplified using the primer pair PfYTH2-HR_F/R (Table S4) and cloned into the NotI and AvrII sites of the pSLI-sandwich

(0807600) plasmid (Addgene plasmid 85790) described in reference 18. *P. falciparum* parasites (strain 3D7) were transfected and selected for integrants as previously described (18). Integration into the correct locus was verified using the primer pairs Locus_F/R, 5' arm_F/R, and 3' arm_F/R (Table S4).

To generate the PfYTH.2-sandwich^{ML} cell line, the PfYTH.2-sandwich parasites were subsequently transfected with a plasmid expressing the Lyn-mCherry plasma membrane mislocalizer (pLYN-FRB-mCherry-nmd3-BSD; Addgene plasmid 85796), and transfectants were selected as previously described (18).

Protein fractionation and Western Blot analysis. Trophozoite-stage parasites were separated from the host red blood cells by incubation with 0.15% saponin (Sigma) followed by centrifugation for 4 min at $2,200 \times g$. The parasite pellet was resuspended in 10 volumes of cytoplasmic extraction buffer (20 mM HEPES [pH 7.9], 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 0.3% NP-40, 1 mM dithiothreitol [DTT], and protease inhibitors), incubated on ice for 5 min, and then centrifuged at $2,200 \times g$ for 5 min at 4°C. The supernatant was collected as the cytoplasmic fraction, and the insoluble pellet was washed three times with the cytoplasmic extraction buffer. The insoluble pellet was incubated in 10 volumes of radioimmunoprecipitation assay (RIPA) buffer (Thermo Fisher) with protease inhibitors and 5 U Benzamide (Millipore). This fraction was then centrifuged at $13,000 \times g$ for 10 min at 4°C to pellet down insoluble aggregates and hemazoin, and the supernatant was collected as the nuclear fraction. Both fractions were boiled at 95°C for 5 min after addition of 6× Laemmli loading dye. Proteins were separated in 12% SDS-polyacrylamide gels and transferred to low-fluorescence polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The blots were blocked with Odyssey blocking buffer (PBS base) (LI-COR) for 1 h at room temperature. Primary antibodies against aldolase (1:3,500; Gentech), GFP (2:3,500; Roche), and histone H3 (1:10,000; Abcam) were incubated overnight at 4°C in blocking buffer. After three washes with 0.1% PBS-Tween 20 (Sigma), appropriate secondary antibodies IRDye 680RD anti-rabbit (1:10,000) and IRDye 800CW anti-mouse (1:10,000) IgG were added to the blot for 1 h at room temperature in blocking buffer with final concentrations of 0.1% Tween 20 (Sigma) and 0.05% sodium dodecyl sulfate (1st Base). The membrane was washed three more times with 0.1% PBS-Tween 20 (Sigma) and once with PBS. Membranes were scanned with a LI-COR Odyssey CLx imager.

Immunofluorescence assay and microscopy. Imaging of fixed PfYTH.2-sandwich parasites was performed as follows. Parasites were smeared onto glass slides, air-dried, and subsequently fixed for 5 min with 4% paraformaldehyde. The slides were blocked with 1% bovine serum albumin (BSA) and permeabilized with 0.1% Tween 20 in 1× PBS at room temperature for 1 h. Slides were then incubated for 1 h at room temperature with mouse anti-GFP antibody (Roche, 1:200). The slides were washed for 15 min with 1× PBST after primary antibody treatment followed by a 1-h incubation at room temperature with secondary antibody (1:10,000, anti-mouse IgG Alexa Fluor-488) and Hoechst (2 μg/ml). Slides were washed with 1× PBST at room temperature. The coverslips were mounted using Fluoromount-G (SouthernBiotech).

The PfYTH.2 fusion protein and the mislocalizer in the PfYTH.2-sandwich^{ML} cell line were visualized on live parasites. Briefly, parasites were incubated with 4',6-diamidino-2-phenylindole (DAPI) for 10 min, washed once with DPBS, mounted on microscope slides, and imaged on a Delta Vision Elite microscope (GE Healthcare). Image overlays were generated using Fiji (39).

PfYTH.2 co-immunoprecipitation and protein mass spectrometry. *P. falciparum* PfYTH.2-sandwich ($n=3$ replicates) and wild-type *P. falciparum* 3D7 ($n=2$ replicates as negative control) were cultured in standard growth medium, sorbitol synchronized, and treated equally for the whole experiment. After 36 h, the parasites were harvested after Percoll (Sigma P4937) enrichment, washed twice with RPMI medium, and cross-linked with 0.5 mM dithiobis(succinimidyl propionate) (DSP) (Thermo Fisher 22585) in PBS for 60 min at 37°C (40). The reaction was quenched with PBS containing 25 mM Tris-HCl. The cell pellets were lysed with RIPA buffer (10 mM Tris HCl [pH 7.5], 150 mM NaCl, 0.1% SDS, and 1% Triton X-100) containing protease and phosphatase inhibitor cocktail (Thermo Fisher 78440). The lysates were cleared by centrifugation at $16,000 \times g$ for 10 min. Supernatants were incubated with anti-GFP magnetic beads (Chromotek gtd-10) overnight at 4°C.

The beads were washed five times with 1 ml RIPA buffer following five washes with 1 ml PBS and one wash with 1 ml 100 mM ammonium bicarbonate (Sigma 09830). The beads were reduced with 10 mM dithiothreitol (Sigma D9779), alkylated with 55 mM iodoacetamide (Sigma I1149), and subjected to on-bead digestion using 1 μg of trypsin (Thermo Fisher 90059). The resulting peptides were desalted using C₁₈ cartridges (Thermo Fisher 89852), and protein mass spectrometry was performed as described above. Candidate PfYTH.2-interacting proteins were filtered by excluding those that were also found in the control samples (e.g., resulting from background binding to antibody-bead complexes), and candidates had to be present with ≥ 2 unique peptides in at least 2 of 3 replicates (Table S2 and Fig. S2D).

Crosslinking PfYTH.2-RNA co-immunoprecipitation followed by RT-qPCR. PfYTH.2-sandwich^{ML} parasites were synchronized to a 6-h window using three consecutive rounds of sorbitol treatments. For the RIP experiment, two biological replicates were collected for the knock-sideways (i.e., plus rapamycin [+RAP]) and (i.e., no rapamycin [−RAP]) control treatment. At 18 h postinfection, rapamycin at a final concentration of 250 nM was added to the knock-sideways group. Three hours later, parasites of the knock-sideways and control treatment were collected by centrifugation (2,200 rpm for 2 min), lysed in 0.075% saponin in DPBS (Thermo Fisher 14190-144), and pelleted by centrifugation at $3,220 \times g$ for 5 min. The pellet was resuspended in 10 ml DPBS, and methanol-free formaldehyde (Thermo Fisher 28908) was added to a final concentration of 1%. The cells were incubated for 10 min at 25°C with gentle agitation before cross-linking was quenched by addition of glycine (final concentration 125 mM) and incubation with gentle agitation for another 5 min at 25°C. Cells were collected by centrifugation ($3,220 \times g$ for 5 min at 4°C), washed twice with ice-cold PBS, and snap-frozen.

For the entirety of the PfYTH.2-RNA co-immunoprecipitation, +RAP and –RAP samples were treated identically. For each sample, 25 μ l Dynabeads protein G magnetic beads (Thermo Fisher 10004D) were washed twice with 1 ml RIPA buffer (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 1% IGEPAL CA-630, 0.1% SDS, and 0.5% sodium deoxycholate) and then resuspended in 1 ml RIPA buffer. One microliter anti-GFP antibody (Abcam ab290) was added to the beads and rotated for 2 h at 4°C to allow binding of the antibody to the beads. In the meantime, cell pellets ($\sim 4 \times 10^8$) were resuspended in 500 μ l RIPA buffer, supplemented with cOmplete Mini EDTA-free proteinase inhibitor (Sigma 4693159001) and 200 U SUPERase-In RNase inhibitor (Thermo Fisher AM2694). The cells were lysed with 200 strokes in a prechilled 2 ml Dounce homogenizer and then sonicated for 5 cycles with settings of 30-s on and 30-s off in a BioRuptor Pico sonicator. The cell lysate was cleared of debris by centrifugation (16,000 $\times g$ for 10 min at 4°C). Following incubation, the antibody (Ab)-bead mixture was washed twice with 1 ml RIPA buffer and then added to the cell lysate and incubated with rotation overnight at 4°C. The beads were collected on a magnet, and the supernatant was discarded. The beads were stringently washed by resuspension and magnet separation twice with RIPA buffer, once with low-salt wash buffer (20 mM Tris-HCl [pH 8], 150 mM NaCl, 2 mM EDTA [pH 8], 1% Triton X-100, and 0.1% SDS), once with high-salt wash buffer (20 mM Tris-HCl [pH 8], 500 mM NaCl, 2 mM EDTA [pH 8], 1% Triton X-100, and 0.1% SDS), and once with LiCl wash buffer (10 mM Tris-HCl [pH 8], 250 mM LiCl, 1 mM EDTA [pH 8], 0.5% IGEPAL CA-630, and 0.5% sodium deoxycholate). The protein-RNA complexes were eluted from the beads by incubation with 205 μ l elution buffer containing 100 pg of a spike-in transcript for 30 min at 70°C. The beads were collected on a magnet, and 200 μ l of the eluate was mixed with 600 μ l of TRIzol LS reagent (Thermo Fisher 10296028). RNA was extracted according to the manufacturer's instructions and precipitated by ethanol precipitation. cDNA was generated using the Superscript VILO cDNA synthesis kit (Thermo Fisher 11754050) according to the manufacturer's protocol. We selected target transcripts that were previously identified to have at least one m⁶A peak at the trophozoite stage (12). Target transcripts were amplified in technical triplicates using Power Sybr green PCR master mix (Thermo Fisher 4367659) and the primers listed in Table S4 on a Bio-Rad CFX qPCR machine. A no-reverse transcription (RT) control (substitution of RT during cDNA synthesis with H₂O) and a no-template control (no cDNA added during qPCR amplification) were included in all experiments. Threshold cycle (C_T) values were normalized to the spike-in transcript (i.e., ΔC_T) in each sample, and relative enrichment for each transcript (i.e., $\Delta\Delta C_T$) was calculated by subtraction of the –RAP ΔC_T from the +RAP ΔC_T in the corresponding control and treatment samples.

PfYTH.2 gradient purification. PfYTH.2-sandwich parasites were synchronized to a 6-h window by three consecutive sorbitol treatments. At 18 hpi, parasites were collected by centrifugation (2,200 rpm for 2 min) and lysed in 0.075% saponin in DPBS (Thermo Fisher 14190-144). The parasite cell pellet was washed twice in cytoplasmic lysis buffer (CLB; 10 mM NaCl, 5 mM MgCl₂, 20 mM Tris HCl [pH 8], and 1% Triton X-100) and snap-frozen at –80°C.

The pellet from $\sim 10^9$ parasite cells was resuspended in 500 μ l CLB supplemented with 200 U SUPERase-In RNase inhibitor (Thermo Fisher AM2694), 100 μ g cycloheximide (Sigma C4859-1ML), and cOmplete Mini EDTA-free proteinase inhibitor (Sigma 4693159001). The cells were lysed in a 2-ml prechilled Dounce homogenizer, and nuclei and cell debris were pelleted by centrifugation (16,100 $\times g$ for 10 min at 4°C). The protein concentration of the supernatant was measured using the Pierce A₆₆₀ reagent (Thermo Fisher 22660) on a NanoDrop (Thermo Fisher). The protein lysates were layered on top of a linear sucrose gradient (10% to 50%) prepared in ultracentrifuge tubes (Beckman Coulter 344059) and fractionated by centrifugation (3 h at 39,000 rpm at 4°C) in a Beckmann coulter ultracentrifuge using a SW-41 swinging bucket rotor. The gradient was fractionated into 10 different fractions on a fraction collector, continuously measuring the 260-nm absorbance, and stored at –80°C.

Proteins were precipitated by adding 10% (vol/vol) trichloroacetic acid to the sucrose fractions and incubating on ice for 4 h. Proteins were pelleted by centrifugation (18,000 $\times g$ for 10 min at 4°C) and washed thrice with ice-cold acetone. The pellet was air dried and resuspended in 10 μ l 4 \times NuPage LDS sample buffer (Thermo Fisher NP0007). For Western Blot analysis, the samples were diluted to a 2 \times NuPage sample buffer concentration using 10 μ l RIPA buffer (50 mM Tris-HCl [pH 7.4], 100 mM NaCl, 1% IGEPAL CA-630, 0.1% SDS, and 0.5% sodium deoxycholate). Proteins were denatured for 10 min at 70°C, run on a NuPage 4% to 12% bis-Tris gel using morpholinepropanesulfonic acid (MOPS) running buffer at 150 V and transferred to a PVDF membrane using a Trans-Blot Turbo transfer pack (Bio-Rad 1704157) with the Trans-Blot Turbo transfer system (Bio-Rad). The membrane was blocked for 1 h in 1% milk in 0.1% Tween 20 in PBS (PBST). GFP-tagged PfYTH.2 was detected using rabbit anti-GFP (ChromoTek [PAPG1]; 1:1,000 in 1% milk-PBST) primary antibody, followed by donkey anti-rabbit (GE number NA934-1ML) secondary antibodies conjugated to HRP (1:5,000 in 1% milk-PBST). The HRP signal was developed using the SuperSignal West Pico chemiluminescent substrate (Thermo Fisher 34580) and imaged with a ChemiDoc XRS+ (Bio-Rad).

Ribosome profiling. PfYTH.2-sandwich^{ML} parasites were synchronized to a 6-h window by three consecutive sorbitol treatments as described above. At 18 hpi, rapamycin was added at a final concentration of 250 nM to the treatment (i.e., knock sideways) group. Three hours later, parasites were collected by centrifugation (2,200 rpm for 2 min) and lysed in 0.075% saponin in DPBS (Thermo Fisher 14190-144). For the ribosome profiling samples, the parasite cell pellet was washed twice in cytoplasmic lysis buffer (CLB; 10 mM NaCl, 5 mM MgCl₂, 20 mM Tris HCl [pH 8], and 1% Triton X-100) and snap-frozen at –80°C. For the ribosome profiling control (no rapamycin) and treatment (with rapamycin) groups, two replicates with $\sim 10^9$ parasites were collected. In parallel, 5 $\times 10^7$ parasite cells from the same replicate samples were resuspended in 700 μ l QIAzol following saponin lysis and stored at –80°C for mRNA sequencing.

Cell lysis was performed as for the PfYTH.2 gradient purification described above but with an additional partial RNA treatment to digest polysomes into individual monosomes. Briefly, the cell pellets were resuspended in 500 μ l CLB supplemented with 200 U SUPERase-In RNase inhibitor (Thermo Fisher

AM2694), 100 μ g cycloheximide (Sigma C4859-1ML), and cOmplete Mini EDTA-free proteinase inhibitor (Sigma 4693159001). Cells were lysed in a 2-ml prechilled Dounce homogenizer and cleared from nuclei and cell debris by centrifugation (16,100 \times g for 10 min at 4°C). The protein concentration of the supernatant was measured using the Pierce A_{660} reagent (Thermo Fisher 22660) on a NanoDrop (Thermo Fisher), and ~600 ng of protein lysate was subjected to partial RNase digestion using 100 U RNase I (Thermo Fisher AM2294) in a thermomixer (5 min at 37°C and 300 rpm). The RNase-treated protein lysates were layered on a linear sucrose gradient (10% to 50%) and fractionated by ultracentrifugation (3 h at 39,000 rpm at 4°C) as described above.

The sucrose gradient was fractionated, and the 80S monosome fraction was detected by the 260-nm absorbance, collected in a microcentrifuge tube, and immediately mixed with TRIzol LS reagent (Thermo Fisher 10296010). The aqueous RNA phase was separated according to the manufacturer's instructions, and RNA was precipitated by isopropanol precipitation and resuspended in 12 μ l RNase-free water. To select the ribosome protected fragments (RPF), 10 μ l of the RNA sample was denatured using 10 μ l 2 \times Novex Tris-borate-EDTA (TBE)-urea sample buffer (Thermo Fisher LC6876) and run on a 15% Novex TBE-urea gel (Thermo Fisher EC6885BOX). As size marker, 25-nt and 32-nt RNA oligonucleotides were run on the same gel. The gel was stained for 30 min in 50 ml RNase free 1 \times TBE buffer supplemented with 5 μ l Sybr gold (Thermo Fisher S11494), and the RPF fraction (25 nt to 32 nt) for each sample was cut from the gel using razor blades. Gel slices were crushed in 1.5-ml tubes and resuspended in 300 μ l gel extraction buffer (0.3 M sodium acetate [NaOAc], 1 mM EDTA, and 0.25% [vol/vol] SDS). The solution was frozen for 30 min on dry ice and then left at 25°C overnight in a thermomixer at 500 rpm. RPFs were extracted from the solution by ethanol precipitation. To allow for adaptor ligation, RPF 3' ends were dephosphorylated using T4 PNK (New England Biolabs M0201S) for 30 min at 37°C, followed by the addition of 10 mM ATP and another 30 min incubation at 37°C for RPF 5' phosphorylation. RPF fragments were purified using ethanol precipitation, and small RNA libraries were prepared using the NEBNext Multiplex small RNA library prep kit for Illumina (New England Biolabs E7300) according to the manufacturer's instructions.

RNA-sequencing. Total RNA from the two replicates of treatment and control P γ YTH.2-sandwich^{ML} collected in parallel with the ribosome profiling samples were extracted as described above. Poly(A) RNA was enriched using the Dynabeads mRNA purification kit (Thermo Fisher 61006). RNA sequencing libraries were prepared using the Illumina TruSeq stranded RNA library prep kit (Illumina RS-122-2101) according to the manufacturer's instructions with slight modifications. To account for the AT richness of cDNA fragments, we used the KAPA HiFi polymerase (Roche 07958846001) at the library amplification step. The libraries were sequenced on an Illumina NextSeq 500 platform with a 2 by 150-bp paired-end read layout.

Analysis of translational efficiencies. Raw image files were converted to fastq sequence files using Illumina's bcl2fastq (v2.19), and adaptors and low-quality read ends were trimmed using Trimmomatic (41). The mRNA and RPF sequencing reads for the two replicates of \pm RAP P γ YTH.2-sandwich^{ML} samples were mapped to the *P. falciparum* genome, and PCR duplicates were removed using SAMtools (42). For the mRNA samples, only read alignments with a MAPQ quality score of \geq 20 were retained. Raw gene count values of the mRNA (strand specific) and ribosome footprints (non-strand specific) were calculated in R using the package htseq-count (43). Gene count tables were merged and the fragments per kilobase of exon per one million mapped reads (FPKM) were calculated in R using the fpkm() function within the DESeq2 package (44). FPKM-derived translational efficiencies were calculated as FPKM(RPF)/FPKM (mRNA). Δ TE values were calculated using DESeq2 integrated in the deltaTE workflow (45) from raw mRNA and RPF values.

Phylogenetic analysis of YTH proteins. Full-length protein sequences of P γ YTH.1, P γ YTH.2, and representative proteins from model eukaryotes were downloaded from UniProt, and multiple-sequence alignments were performed using mafft (46) with default settings. Gaps were removed with trimAl (47), and the best phylogenetic model (i.e., WAG) was calculated using ProtTest3 (48). A maximum likelihood phylogenetic tree was constructed using MEGA (v7) (49) with the WAG model and 1,000 bootstrap replicates. The bootstrap consensus trees were visualized in FigTree (v1.4.3, <http://tree.bio.ed.ac.uk/software/figtree/>).

Statistical analysis. All statistical analyses were performed in R (50). To test for a normal distribution of the data, the Shapiro-Wilk normality test was used. To test for significance between two groups, a two-sided independent-samples *t* test or two-sided Mann-Whitney *U* test was performed where indicated. Gene ontology enrichments were calculated using the build-in tool at <https://plasmoDB.org>. Correlations were calculated in R using function cor() with default settings (i.e., calculation of Pearson correlation coefficient *r*).

Data availability. Ribosome profiling and mRNA sequencing data were deposited under NCBI BioProject PRJNA659894. RNA modification mass spectrometry, proteomics data of the RNA oligonucleotide pulldown, and the P γ YTH.2 co-immunoprecipitation data are available at <https://chorusproject.org/> with accession number 1694.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

FIG S1, PDF file, 0.7 MB.

FIG S2, PDF file, 0.8 MB.

FIG S3, PDF file, 1.2 MB.

TABLE S1, XLSX file, 0.1 MB.

TABLE S2, XLSX file, 0.1 MB.

TABLE S3, XLSX file, 0.8 MB.

TABLE S4, XLSX file, 0.1 MB.

ACKNOWLEDGMENTS

We thank Micheline Fromont and Diana Baquero for providing the equipment for ribosome profiling experiments. Sequencing was performed at the Biomix center at the Institut Pasteur. Pictures were created in part with BioRender.

This work was supported by a European Research Council Advanced Grant (PlasmoSilencing 670301) and the French Parasitology consortium ParaFrap (ANR-11-LABX0024) awarded to A. Scherf. S.B. is supported by an EMBO Advanced Long-Term Fellowship (aALTF 632-2018). P.R.P., P.C.D., J.L., and A. Sinha were supported by the National Research Foundation Singapore under its Singapore-MIT Alliance for Research and Technology (SMART) Centre, Antimicrobial Resistance IRG and Singapore Ministry of Education Academic Research Fund Tier 2 (MOE2018-T2-2-131). A. Sinha and J.L. acknowledge support from the Singapore-MIT Alliance (SMA) Graduate Fellowship. Proteomics work was performed in part in the Center for Environmental Health Sciences BioCore, which is supported by Center grant P30-ES002109 from the National Institute of Environmental Health Sciences. We also acknowledge Peiyong Ho and Tan Tse Mien for providing support at SMART laboratories in Singapore. G.C. and M.S. were funded by a European Research Council (ERC) Starting Grant (ERC-StG-679243). Work on this project in the laboratory of S.A.R. is funded by a grant from the Australian National Health and Medical Research Council (1165354) and by a grant from the Australian Research Council (DP160100389).

S.B., A. Sinha, and S.A.R. conceptualized the project. S.B., A. Sinha, J.M.B., S.A.R., A.D., and E.M. conceived experiments. A.D., E.M., and S.A.R. generated cell lines. P.C. performed recombinant PfYTH.2 experiments. A. Sinha and J.L. performed and analyzed LC-MS/MS, protein co-immunoprecipitation, and RNA-protein experiments. S.B. and M.S. performed ribosome profiling. S.B. analyzed sequencing experiments. P.R.P., P.C.D., G.C., S.A.R., and A. Scherf supervised and helped interpret analyses. All authors discussed and approved the manuscript.

We declare no competing interests.

REFERENCES

- World Health Organization. 2019. World malaria report 2018. World Health Organization, Geneva, Switzerland.
- Modrzynska K, Pfander C, Chappell L, Yu L, Suarez C, Dundas K, Gomes AR, Goulding D, Rayner JC, Choudhary J, Billker O. 2017. A knockout screen of ApiAP2 genes reveals networks of interacting transcriptional regulators controlling the *Plasmodium* life cycle. *Cell Host Microbe* 21:11–22. <https://doi.org/10.1016/j.chom.2016.12.003>.
- Balaji S, Babu MM, Iyer LM, Aravind L. 2005. Discovery of the principal specific transcription factors of apicomplexa and their implication for the evolution of the AP2-integrase DNA binding domains. *Nucleic Acids Res* 33:3994–4006. <https://doi.org/10.1093/nar/gki709>.
- Toenhake CG, Fraszka SA-K, Vijayabaskar MS, Westhead DR, van Heeringen SJ, Bártfai R. 2018. Chromatin accessibility-based characterization of the gene regulatory network underlying *Plasmodium falciparum* blood-stage development. *Cell Host Microbe* 23:557.e9–569.e9. <https://doi.org/10.1016/j.chom.2018.03.007>.
- Bozdech Z, Llinás M, Pulliam BL, Wong ED, Zhu J, DeRisi JL. 2003. The transcriptome of the intraerythrocytic developmental cycle of *Plasmodium falciparum*. *PLoS Biol* 1:e5. <https://doi.org/10.1371/journal.pbio.0000005>.
- Flueck C, Bartfai R, Volz J, Niederwieser I, Salcedo-Amaya AM, Alako BT, Ehlgren F, Ralph SA, Cowman AF, Bozdech Z, Stunnenberg HG, Voss TS. 2009. *Plasmodium falciparum* heterochromatin protein 1 marks genomic loci linked to phenotypic variation of exported virulence factors. *PLoS Pathog* 5:e1000569. <https://doi.org/10.1371/journal.ppat.1000569>.
- Sinha A, Hughes KR, Modrzynska KK, Otto TD, Pfander C, Dickens NJ, Religa AA, Bushell E, Graham AL, Cameron R, Kafack BFC, Williams AE, Llinás M, Berriman M, Billker O, Waters AP. 2014. A cascade of DNA-binding proteins for sexual commitment and development in *Plasmodium*. *Nature* 507:253–257. <https://doi.org/10.1038/nature12970>.
- Kafack BFC, Rovira-Graells N, Clark TG, Bancells C, Crowley VM, Campino SG, Williams AE, Drought LG, Kwiatkowski DP, Baker DA, Cortés A, Llinás M. 2014. A transcriptional switch underlies commitment to sexual development in malaria parasites. *Nature* 507:248–252. <https://doi.org/10.1038/nature12920>.
- Painter HJ, Chung NC, Sebastian A, Albert I, Storey JD, Llinás M. 2018. Genome-wide real-time *in vivo* transcriptional dynamics during *Plasmodium falciparum* blood-stage development. *Nat Commun* 9:2656. <https://doi.org/10.1038/s41467-018-04966-3>.
- Caro F, Ah Yong V, Betegon M, DeRisi JL. 2014. Genome-wide regulatory dynamics of translation in the *Plasmodium falciparum* asexual blood stages. *Elife* 3:e04106. <https://doi.org/10.7554/eLife.04106>.
- Shock JL, Fischer KF, DeRisi JL. 2007. Whole-genome analysis of mRNA decay in *Plasmodium falciparum* reveals a global lengthening of mRNA half-life during the intra-erythrocytic development cycle. *Genome Biol* 8:R134. <https://doi.org/10.1186/gb-2007-8-7-r134>.
- Baumgarten S, Bryant JM, Sinha A, Reyser T, Preiser PR, Dedon PC, Scherf A. 2019. Transcriptome-wide dynamics of extensive m⁶A mRNA methylation during *Plasmodium falciparum* blood-stage development. *Nat Microbiol* 4:2246–2259. <https://doi.org/10.1038/s41564-019-0521-7>.
- Zaccara S, Jaffrey SR. 2020. A unified model for the function of YTHDF proteins in regulating m⁶A-modified mRNA. *Cell* 181:1582–1595. <https://doi.org/10.1016/j.cell.2020.05.012>.
- Patil DP, Pickering BF, Jaffrey SR. 2018. Reading m⁶A in the transcriptome: m⁶A-binding proteins. *Trends Cell Biol* 28:113–127. <https://doi.org/10.1016/j.tcb.2017.10.001>.
- Patil DP, Chen CK, Pickering BF, Chow A, Jackson C, Guttman M, Jaffrey SR. 2016. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. *Nature* 537:369–373. <https://doi.org/10.1038/nature19342>.

16. Luo S, Tong L. 2014. Molecular basis for the recognition of methylated adenines in RNA by the eukaryotic YTH domain. *Proc Natl Acad Sci U S A* 111:13834–13839. <https://doi.org/10.1073/pnas.1412742111>.
17. Theler D, Dominguez C, Blatter M, Boudet J, Allain FH-T. 2014. Solution structure of the YTH domain in complex with N⁶-methyladenosine RNA: a reader of methylated RNA. *Nucleic Acids Res* 42:13911–13919. <https://doi.org/10.1093/nar/gku1116>.
18. Birnbaum J, Flemming S, Reichard N, Soares AB, Mesén-Ramírez P, Jonscher E, Bergmann B, Spielmann T. 2017. A genetic system to study *Plasmodium falciparum* protein function. *Nat Methods* 14:450–456. <https://doi.org/10.1038/nmeth.4223>.
19. Zhang M, Wang C, Otto TD, Oberstaller J, Liao X, Adapa SR, Udenze K, Bronner IF, Casandra D, Mayho M, Brown J, Li S, Swanson J, Rayner JC, Jiang RHY, Adams JH. 2018. Uncovering the essential genes of the human malaria parasite *Plasmodium falciparum* by saturation mutagenesis. *Science* 360:eaap7847. <https://doi.org/10.1126/science.aap7847>.
20. Ingolia NT, Hussmann JA, Weissman JS. 2019. Ribosome profiling: global views of translation. *Cold Spring Harb Perspect Biol* 11:a032698. <https://doi.org/10.1101/cshperspect.a032698>.
21. Ng CS, Sinha A, Aniwah Y, Nah Q, Ramesh Babu I, Gu C, Chionh YH, Dedon PC, Preiser PR. 2018. tRNA epitranscriptomics and biased codon are linked to proteome expression in *Plasmodium falciparum*. *Mol Syst Biol* 14:e8009. <https://doi.org/10.15252/msb.20178009>.
22. Huang H, Weng H, Sun W, Qin X, Shi H, Wu H, Zhao BS, Mesquita A, Liu C, Yuan CL, Hu Y-C, Hüttelmaier S, Skibbe JR, Su R, Deng X, Dong L, Sun M, Li C, Nachtergaele S, Wang Y, Hu C, Ferchen K, Greis KD, Jiang X, Wei M, Qu L, Guan J-L, He C, Yang J, Chen J. 2018. Recognition of RNA N⁶-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. *Nat Cell Biol* 20:285–295. <https://doi.org/10.1038/s41556-018-0045-z>.
23. Zhou KI, Pan T. 2018. An additional class of m⁶A readers. *Nat Cell Biol* 20:230–232. <https://doi.org/10.1038/s41556-018-0046-y>.
24. Edupuganti RR, Geiger S, Lindeboom RGH, Shi H, Hsu PJ, Lu Z, Wang S-Y, Baltissen MPA, Jansen PWT, Rossa M, Müller M, Stunnenberg HG, He C, Carell T, Vermeulen M. 2017. N⁶-methyladenosine (m⁶A) recruits and repels proteins to regulate mRNA homeostasis. *Nat Struct Mol Biol* 24:870–878. <https://doi.org/10.1038/nsmb.3462>.
25. Arguello AE, DeLiberto AN, Kleiner RE. 2017. RNA Chemical proteomics reveals the N⁶-methyladenosine (m⁶A)-regulated protein-RNA interactome. *J Am Chem Soc* 139:17249–17252. <https://doi.org/10.1021/jacs.7b09213>.
26. Worpenberg L, Paolantoni C, Longhi S, Mulorz MM, Lence T, Wessels H-H, Dassi E, Aiello G, Sutandy FXR, Scheibe M, Edupuganti RR, Busch A, Möckel MM, Vermeulen M, Butter F, König J, Notarangelo M, Ohler U, Dieterich C, Quattrone A, Soldano A, Roignant J-Y. 2021. Ythdf is a N⁶-methyladenosine reader that modulates Fmr1 target mRNA selection and restricts axonal growth in *Drosophila*. *EMBO J* 40:e104975. <https://doi.org/10.15252/emboj.2020104975>.
27. Minns AM, Hart KJ, Subramanian S, Hafenstein S, Lindner SE. 2018. Nuclear, cytosolic, and surface-localized poly(A)-binding proteins of *Plasmodium yoelii*. *mSphere* 3:e00435-17. <https://doi.org/10.1128/mSphere.00435-17>.
28. Mangus DA, Evans MC, Jacobson A. 2003. Poly(A)-binding proteins: multifunctional scaffolds for the post-transcriptional control of gene expression. *Genome Biol* 4:223. <https://doi.org/10.1186/gb-2003-4-7-223>.
29. Hillier C, Pardo M, Yu L, Bushnell E, Sanderson T, Metcalf T, Herd C, Anar B, Rayner JC, Billker O, Choudhary JS. 2019. Landscape of the *Plasmodium* interactome reveals both conserved and species-specific functionality. *Cell Rep* 28:1635–1647.e5. <https://doi.org/10.1016/j.celrep.2019.07.019>.
30. Eulalio A, Huntzinger E, Izaurralde E. 2008. GW182 interaction with Argonaute is essential for miRNA-mediated translational repression and mRNA decay. *Nat Struct Mol Biol* 15:346–353. <https://doi.org/10.1038/nsmb.1405>.
31. Szostak E, García-Beyaert M, Guitart T, Graindorge A, Coll O, Gebauer F. 2018. Hrp48 and eIF3d contribute to *msl-2* mRNA translational repression. *Nucleic Acids Res* 46:4099–4113. <https://doi.org/10.1093/nar/gky246>.
32. Peter D, Igreja C, Weber R, Wohlbold L, Weiler C, Ebertsch L, Weichenrieder O, Izaurralde E. 2015. Molecular architecture of 4E-BP translational inhibitors bound to eIF4E. *Mol Cell* 57:1074–1087. <https://doi.org/10.1016/j.molcel.2015.01.017>.
33. Ries RJ, Zaccara S, Klein P, Olererin-George A, Namkoong S, Pickering BF, Patil DP, Kwak H, Lee JH, Jaffrey SR. 2019. m⁶A enhances the phase separation potential of mRNA. *Nature* 571:424–428. <https://doi.org/10.1038/s41586-019-1374-1>.
34. Bennis S, von Bohl A, Ngwa CJ, Henschel L, Kuehn A, Pilch N, Weißbach T, Rosinski AN, Scheuermayer M, Repnik U, Przyborski JM, Minns AM, Orchard LM, Griffiths G, Lindner SE, Llinás M, Pradel G. 2018. A seven-helix protein constitutes stress granules crucial for regulating translation during human-to-mosquito transmission of *Plasmodium falciparum*. *PLoS Pathog* 14:e1007249. <https://doi.org/10.1371/journal.ppat.1007249>.
35. Mair GR, Lasonder E, Garver LS, Franke-Fayard BMD, Carret CK, Wiegant JCAG, Dirks RW, Dimopoulos G, Janse CJ, Waters AP. 2010. Universal features of post-transcriptional gene regulation are critical for *Plasmodium* zygote development. *PLoS Pathog* 6:e1000767. <https://doi.org/10.1371/journal.ppat.1000767>.
36. Mair GR, Braks JAM, Garver LS, Wiegant JCAG, Hall N, Dirks RW, Khan SM, Dimopoulos G, Janse CJ, Waters AP. 2006. Regulation of sexual development of *Plasmodium* by translational repression. *Science* 313:667–669. <https://doi.org/10.1126/science.1125129>.
37. Lindner SE, Swearingen KE, Shears MJ, Walker MP, Vrana EN, Hart KJ, Minns AM, Sinnis P, Moritz RL, Kappe SHL. 2019. Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoites. *Nat Commun* 10:4964. <https://doi.org/10.1038/s41467-019-12936-6>.
38. Perkins DN, Pappin DJ, Creasy DM, Cottrell JS. 1999. Probability-based protein identification by searching sequence databases using mass spectrometry data. *Electrophoresis* 20:3551–3567. [https://doi.org/10.1002/\(SICI\)1522-2683\(19991201\)20:18<3551::AID-ELPS3551>3.0.CO;2-2](https://doi.org/10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2).
39. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, Preibisch S, Rueden C, Saalfeld S, Schmid B, Tinevez J-Y, White DJ, Hartenstein V, Eliceiri K, Tomancak P, Cardona A. 2012. Fiji: an open-source platform for biological-image analysis. *Nat Methods* 9:676–682. <https://doi.org/10.1038/nmeth.2019>.
40. Mesén-Ramírez P, Reinsch F, Blancke Soares A, Bergmann B, Ullrich A-K, Tenzer S, Spielmann T. 2016. Stable translocation intermediates Jam global protein export in *Plasmodium falciparum* parasites and link the PTEX component EXP2 with translocation activity. *PLoS Pathog* 12:e1005618. <https://doi.org/10.1371/journal.ppat.1005618>.
41. Bolger AM, Lohse M, Usadel B. 2014. Trimmomatic: a flexible trimmer for Illumina sequence data. *Bioinformatics* 30:2114–2120. <https://doi.org/10.1093/bioinformatics/btu170>.
42. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G, Durbin R, 1000 Genome Project Data Processing Subgroup. 2009. The Sequence Alignment/Map format and SAMtools. *Bioinformatics* 25:2078–2079. <https://doi.org/10.1093/bioinformatics/btp352>.
43. Anders S, Pyl PT, Huber W. 2015. HTSeq—a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31:166–169. <https://doi.org/10.1093/bioinformatics/btu638>.
44. Love MI, Huber W, Anders S. 2014. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15:550. <https://doi.org/10.1186/s13059-014-0550-8>.
45. Chothani S, Adami E, Ouyang JF, Viswanathan S, Hubner N, Cook SA, Schafer S, Rackham OJL. 2019. deltaTE: detection of translationally regulated genes by integrative analysis of Ribo-seq and RNA-seq data. *Curr Protoc Mol Biol* 129:e108. <https://doi.org/10.1002/cpmb.108>.
46. Katoh K, Standley DM. 2013. MAFFT multiple sequence alignment software version 7: improvements in performance and usability. *Mol Biol Evol* 30:772–780. <https://doi.org/10.1093/molbev/mst010>.
47. Capella-Gutierrez S, Silla-Martinez JM, Gabaldon T. 2009. trimAl: a tool for automated alignment trimming in large-scale phylogenetic analyses. *Bioinformatics* 25:1972–1973. <https://doi.org/10.1093/bioinformatics/btp348>.
48. Darriba D, Taboada GL, Doallo R, Posada D. 2011. ProtTest 3: fast selection of best-fit models of protein evolution. *Bioinformatics* 27:1164–1165. <https://doi.org/10.1093/bioinformatics/btr088>.
49. Kumar S, Stecher G, Tamura K. 2016. MEGA7: Molecular Evolutionary Genetics Analysis version 7.0 for bigger datasets. *Mol Biol Evol* 33:1870–1874. <https://doi.org/10.1093/molbev/msw054>.
50. Development Core Team R. 2012. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
51. Oates ME, Romero P, Ishida T, Ghalwash M, Mizianty MJ, Xue B, Dosztányi Z, Uversky VN, Obradovic Z, Kurgan L, Dunker AK, Gough J. 2013. D²P²: database of disordered protein predictions. *Nucleic Acids Res* 41:D508–D516. <https://doi.org/10.1093/nar/gks1226>.
52. Tóth DJ, Tóth JT, Gulyás G, Balla A, Balla T, Hunyady L, Várnai P. 2012. Acute depletion of plasma membrane phosphatidylinositol 4,5-bisphosphate impairs specific steps in endocytosis of the G-protein-coupled receptor. *J Cell Sci* 125:2185–2197. <https://doi.org/10.1242/jcs.097279>.